Invitrocue Limited announced that a clinical validation study is underway for its Onco-PDOTM test with Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center Munich, Germany. The study, titled IVQ-Rechts der Isar Validation Study 2019, will establish patient-derived organoids (PDOs) using biopsy samples taken from patients with high-risk breast cancer. The PDOs will be tested against a panel of cancer drugs (including standard of care drugs). Drug responses in PDOs will then be compared to the responses of actual patients undergoing chemotherapy treatme nt in the clinic. The results will serve as an indication of the predictive value of the Onco-PDOTM test for personalized cancer treatment. Most cancer treatments have a "one-size-fits-all" approach where different patients are given the same cancer drugs. The Onco-PDOTM technology will allow scientists at IVQ to test patient-derived organoids against a panel of chemotherapeutic drugs. The results will allow physicians to make a more informed decision about the most appropriate cancer drugs and treatment regimen for that individual patient. This potentially eliminates unnecessary side effects from futile treatments, saves precious time for the patient and reduces costs for the healthcare system. Study may benefit many European cancer patients. The study is an important step for Invitrocue as it will potentially allow the Company's personalised oncology approach to benefit cancer patients in Europe. Germany alone had 608,742 new cancer cases in 2018, with 11.8% being breast cancer cases. The first cohort of the study consists of 20 patients, with results expected within third quarter of 2019. Initial results have been positive. The second cohort consists of 60 patients.